MapLight Therapeutics, Inc. (MPLT) stock
MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.57−0.33 (-4.78%)
Close on Nov 17, 2026Market cap $304.70MP/E –Yield –
MapLight Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
MapLight Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $198.84M, up 136.3% year over year. For fiscal 2025 it was $138.35M, up 101.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.35M | +101.9% |
| FY2024 | Dec 31, 2024 | $68.52M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $53.44M | +99.0% |
| Q1 FY2026 | Mar 31, 2026 | $53.68M | +171.3% |
| Q4 FY2025 | Dec 31, 2025 | $64.62M | +212.0% |
| Q3 FY2025 | Sep 30, 2025 | $27.09M | +61.1% |
| Q2 FY2025 | Jun 30, 2025 | $26.85M | – |
| Q1 FY2025 | Mar 31, 2025 | $19.79M | – |
| Q4 FY2024 | Dec 31, 2024 | $20.71M | – |
| Q3 FY2024 | Sep 30, 2024 | $16.81M | – |
See a number that looks wrong?